Nirmatrelvir-Ritonavir continues to be recommended for outpatient treatment of COVID-19 infections, especially as cases continue to rise. However, this therapy does present clinical challenges – from drug interactions to off-label dosing and rebound COVID-19 infections, therapy is not as easy as it sounds. Listen as host Geoff Wall describes the clinical challenges and guest Jake Galdo describes the public health considerations for nirmatrelvir-ritonavir use.
The GameChanger
Nirmatrelvir-ritonavir has significant clinical challenges including various drug interactions with DOACs, statins, amiodarone, and tacrolimus, for example. It’s also important to note that COVID-19 rebound after nirmatrelvir-ritonavir is not due to resistance based on the latest data.
Show Segments
00:00 – Introductions
01:25 – Nirmatrelvir-Ritonavir Updates
04:27 – Nirmatrelvir-Ritonavir Controversy
06:30 – Drug Interactions
08:05 – DOACs and Nirmatrelvir-Ritonavir
11:44 – Statin and Nirmatrelvir-Ritonavir
13:04 – Amiodarone and Nirmatrelvir-Ritonavir
15:02 – Tacrolimus and Nirmatrelvir-Ritonavir
19:33 – COVID-19 Rebound
23:38 – Equity and Access
31:44 – Closing Remarks
Host
Geoff Wall, PharmD, BCPS, FCCP, CGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
Guest
John A. Galdo, PharmD, MBA, BCPS, BCGP (Jake)
Course Content and Developer, CEimpact
Pharmacist, Ross Bridge Pharmacy
CEO, Seguridad, Inc
Dr. Galdo have no relevant financial relationships to disclose.
References and Resources
Redeem your CPE or CME credit
Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode)
Continuing Education Information
Learning Objectives:
1. Explain common drug interactions associated with Nirmatrelvir-Ritonavir
2. Discuss COVID ‘rebound’ infections
3. Describe public health and healthcare data considerations for Nirmatrelvir-Ritonavir use
0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-22-247-H01-P
Initial release date: 07/11/22
Expiration date: 07/11/2023
Additional CPE & CME details can be found here